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Abstract
Background—Frequency of drug changes in combination antiretroviral therapy among patients
starting both tuberculosis (TB) and human immunodeficiency virus (HIV) therapy, as a result of
treatment-limiting toxicity or virological failure, is not well established.
Methods—Patients in the Starting Antiretroviral Therapy at Three Points in Tuberculosis
(SAPiT) trial were randomized to initiate antiretroviral therapy either early or late during TB
treatment or after completion of TB treatment. Drug changes due to toxicity (defined as due to
grade 3 or 4 adverse events) or virological failure (defined as viral load > 1000 copies/ml on two
occasions, taken at least 4 weeks apart) were assessed in these patients.
Results—A total of 501 TB-HIV co-infected patients were followed for a mean of 16.0 (95%
confidence interval (CI): 15.5 to 16.6) months after antiretroviral therapy (ART) initiation. The
standard first-line ARVs used, were efavirenz, lamivudine and didanosine. Individual drug
switches for toxicity occurred in 14 patients (incidence rate: 2.1 per 100 person-years; 95% (CI):
1.1 to 3.5), and complete regimen changes due to virological failure in 25 patients (incidence rate:
3.7 per 100 person-years; CI: 2.4 to 5.5). The most common treatment limiting toxicities were
neuropsychiatric effects (n=4; 0.8%), elevated transaminase levels and hyperlactatemia (n= 3;
0.6%), and peripheral neuropathy (n=2; 0.4%). Complete regimen change due to treatment failure
was more common in patients with CD4+ cell count <50cells/mm3 (p<0.001) at ART initiation
and body mass index greater than 25 kg/m2 (p=0.01) at entry into the study.
Conclusion—Both drug switches and complete regimen change were uncommon in patients co-
treated for TB-HIV with the chosen regimen. Patients with severe immunosuppression need to be
monitored carefully, as they were most at risk for treatment failure requiring regimen change.
Introduction
There were an estimated 8.7 million cases of tuberculosis (TB) in 2011, approximately 1.1
million of which were co-infected with human immunodeficiency virus HIV [1]. Sub-
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Saharan Africa accounted for 80% of the global burden of TB–HIV co-infections [1]. Co-
treatment of these diseases presents several management challenges. Treatment-limiting
toxicity is an important concern when integrating TB-HIV treatment. Other concerns include
drug interactions between rifampicin and some classes of antiretrovirals [2], immune
reconstitution inflammatory syndrome (IRIS) and high pill burden [3, 4].
These clinical challenges potentially undermine the success of both HIV and TB control
programs, contribute to the poor tolerability of combined antiretroviral therapy (ART) and
TB therapy, and impact on treatment adherence. There is now evidence that initiating ART
during TB therapy in co-infected patients significantly reduces mortality, and improves
outcomes in both conditions [5–8]. However, these benefits need to be weighed against the
risks of morbidity due to treatment interruptions, toxicity or treatment failure.
There are limited prospective data from randomized controlled trials available to inform
clinical guidelines. In this paper we report the incidence, predictors of, and reasons for ART
changes, in a cohort of TB-HIV co-infected patients enrolled in a randomized controlled
trial designed to determine the optimal time to initiate ART in TB treatment.
Methods
Study Design and Participants
The Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT) trial was an
open label, three-arm, randomized, controlled trial, which enrolled 642 patients between
June 2005 and July 2008, to determine the optimal timing of ART initiation in TB-HIV co-
infected patients. Details of the study design and procedures and the primary outcomes of
the study have been described previously [5, 6]. In brief, TB-HIV co-infected patients, aged
18 years or older (screening CD4+ count < 500 cells/mm3), were enrolled at the CAPRISA
eThekwini clinical research site, which adjoins the Prince Cyril Zulu Communicable
Disease Centre (PCZCDC), in Durban, South Africa. HIV-infection was confirmed by two
rapid HIV tests and pulmonary TB (PTB) was confirmed by acid fast bacilli smear
positivity.
Study Procedures
Patients were randomized to initiate ART within 4 weeks of tuberculosis treatment initiation
(early integrated treatment arm), within 4 weeks after completion of intensive phase of
tuberculosis treatment (late integrated treatment arm), or within 4 weeks after tuberculosis
therapy completion (sequential treatment arm). Patients were initiated on a once daily ART
regimen consisting of efavirenz 600mg, lamivudine 300mg and enteric-coated didanosine
250mg (weight <60kg) or 400mg (weight ≥ 60kg). All first episode PTB was treated with a
fixed–dose combination of rifampicin, isoniazid, ethambutol and pyrazinamide according to
pre-treatment weight for 2 months (intensive phase), with subsequent fixed-dose
combination of isoniazid and rifampicin for 4 months (continuation phase). Patients with re-
treatment PTB received a 60-day intensive phase which included streptomycin, followed by
a 100-day continuation phase, in accordance with the national policy. Patients were offered
community- or clinic-based directly observed therapy. All patients received a standard
package of care which included adherence counseling and cotrimoxazole prophylaxis.
Additionally, female patients were required to use hormonal contraception while on
efavirenz.
Follow-up visits for the monitoring of safety, clinical status and adherence to ART were
scheduled monthly for 24 months. Laboratory investigations included baseline (at screening
and enrolment) CD4+ cell count using a FACS flow cytometer (Becton Dickinson, Franklin
Lakes NJ, USA), viral load by HIV RNA PCR (Roche Cobas Amplicor HIV-1 Monitor
Naidoo et al. Page 2













v1.5-lower limit of detection 400 copies/ml), full blood counts, urea, electrolytes, creatinine,
liver function, Hepatitis B surface antigen tests and syphilis serology. These investigations
were done at baseline and repeated every 6 months or earlier, if clinically indicated. ART
adherence was assessed monthly using pharmacy pill counts. Pillcounts were assessed based
on the number of pills dispensed and physically returned. In addition we took into account
lost doses and remaining doses reported on previously that may have been returned at a
subsequent visit.
Adverse events were graded with the use of the Division of AIDS Table for Grading the
Severity of Adult and Pediatric Adverse Events (Version 1.0) [9]. A toxicity grading of 3 or
4 was used as indication for discontinuation or substitution of specific antiretroviral drugs,
and referred to as drug switch due to toxicity. Drug switch could also occur as a result of
contraindication or drug interaction.
Virological failure, defined as a viral load > 1000copies/ml on two occasions, taken at least
4 weeks apart, resulted in discontinuation or complete regimen change of all first line ART
drugs. Viral suppression or undetectable viral load was defined as a viral load of < 400
copies/ml. Drug changes therefore referred to both individual drug switches, as a result of
toxicity, and to complete regimen changes, as a result of virological failure. The most
commonly utilised (72%) second line regimen in patients requiring complete regimen
change comprised, lopinavir/ritonavir, tenofovir and zidovudine.
Study Oversight
Ethical approval for the study was provided by the Biomedical Research Ethics Committee
of the University of KwaZulu-Natal (E107/05), and the Medicines Control Council of South
Africa (MCC Ref: 20060157).
Statistical analysis
This analysis was based on a 24 months post randomization follow-up time period to allow
for the patients in the sequential treatment arm to have sufficient time on antiretroviral
therapy to be comparable to the other two arms.
Time at risk was calculated from ART initiation to the date on which drugs were stopped,
death, withdrawal or termination from the study. For patients who changed drugs more than
once, only the first change was included in the incidence rate calculation. Confidence
intervals (CI) for incidence and incidence rate ratios (IRR) assumed a Poisson distribution.
Multivariate Cox proportional hazards regression models were used separately for drug
switch and complete regimen change to assess the risk factors for regimen changes. Data
published in 2010 [5] provided interim results following the September 2008 safety
monitoring committee review. Results presented in 2011 were based on the complete set of
trial data [6]. The data presented in this paper, in addition, cover the full 24-month follow-up
period post randomization. All statistical tests were two sided. Fisher’s Exact test or Fisher-
Freeman-Halton test was used for the analysis of categorical data. The T-test for
independent samples, Wilcoxon two-sample, one way ANOVA or the Kruskal-Wallis tests
were used for the analysis of continuous data. Statistical analysis was done using SAS
(version 9.2.; SAS Institute Inc., Cary, NC, USA).
Results
Of 1331 patients screened for eligibility, 642 were enrolled and randomized into the study,
with 501 initiating ART; 198 (92.5%); 164 (76.3%); 139 (65.3%) in the early integrated, late
integrated and sequential arms respectively (Figure 1). Patients were followed for an average
of 17.6 (95% CI: 16.6 to 18.6); 16.8 (95% CI: 16.0 to 17.6) and 13.0 (95% CI: 12.3 to 13.7)
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months after ART initiation, with a retention rate at 24 months post randomization of 76.6%,
71.2% and 71.3%, in the early integrated, late integrated and sequential arms respectively.
Baseline results
There were differences only for weight (p=0.01) and haemoglobin (p<0.001) across the
three treatment arms, and CD4+ cell counts were lower in in patients who had drug changes
(p=0.01) (Table 1). At baseline, the proportion of patients with Hepatitis B surface
antigenaemia, peripheral neuropathy and raised transaminases-(≥5 times the upper limit of
normal) were similar across the three treatment arms (Table 1).
Incidence of complete regimen change and drug switch across the three treatment arms
ART changes occurred in 39/501 patients, with an incidence rate (IR) of 5.8 (95% CI: 4.1 to
8.0) per 100 person-years (py). One participant experienced two individual drug switches for
different reasons. Among14/501 (2.8%) patients, drug switches for toxicity occurred at a
median time of 3.6 months (IQR: 2.5 to 6.9) post ART initiation, with an incidence rate of
2.1 (95% CI: 1.1 to 3.5). Complete regimen change occurred in 25/501 (5.0%), with an
incidence rate of 3.7 (95% CI: 2.4 to 5.5) per 100 py. There was no significant difference in
the incidence of individual drug switches or complete regimen changes between the three
arms (p=0.25). There were no differences in median time to single drug switches (p=0.64)
and complete regimen changes (p=0.86) across the three treatment arms. Incidence of
complete regimen changes in the early integrated treatment arm was 2.3 per 100 py (95%
CI: 0.9 to 4.8) compared to 3.9 per 100 py (95% CI: 1.8 to 7.4) in the late integrated
treatment arm (IRR: 0.6; 95% CI: 0.2 to 1.8; p=0.37) and 5.9 per 100 py (95% CI: 2.7 to
11.1) in the sequential treatment arm (IRR: 0.4; (95% CI: 0.1 to 1.2; p=0.19) (Table 2). In
patients with CD4+ cell counts < 50cells/mm3, the incidence of complete regimen change
was 5.5 (95% CI: 1.1 to 16.1), 12.9 (95% CI: 4.7 to 28.2) and 13.4 (95% CI: 2.8–39.3) per
100 py in the early integrated, late integrated and sequential treatment arms respectively
(p=0.53). In patients with CD4+ count> 50cells/mm3, the incidence of complete regimen
change was 1.6 (95% CI: 0.4 to 4.2), 1.6 (95% CI: 0.3 to 4.8 and 4.6 (95% CI: 1.7 to 10.0)
per 100 py in the early integrated, late integrated and sequential treatment arm, respectively
(p=0.17).
Reasons for drug switches
The reasons for and time to individual drug switches from ART initiation are shown in
Table 3. We found the most common treatment-limiting toxicities to be neuropsychiatric
effects (n=4; 0.8%) elevated transaminases and hyperlactatemia (n= 3; 0.6%) and peripheral
neuropathy (n=2; 0.4%). Eleven of the 15 drug switches occurred within the first 6 months
after ART initiation. Among the 14 patients with drug switches, five were on concurrent
TB-HIV treatment. Five patients in each of the early and late treatments arms and one in the
sequential treatment arm experienced ART treatment interruptions due to toxicity, but these
toxicities did not lead to any drug switches.
Complete Regimen Change
The median time to complete regimen change from ART initiation was 9,9 (IQR: 6.4 to
13.0), 10.4 (IQR: 9.7 to 11.0), 9.5 (IQR: 8.1 to 10.9) months with no significant difference
between the arms (p=0.64). Among the patients with complete regimen change none were
on concurrent TB therapy at the time of regimen change. The median viral load before
complete regimen change was 4.9 (IQR: 4.3 to 5.6) log copies/ml. Virologic suppression
rates were high in all treatment arms after 18 months of follow-up [5, 6].
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The overall adherence at 24 months post ART initiation, based on pill count data, was
similar across the 3 treatment arms (p=0.64). Among patients with drug changes, the
adherence rates were 90.4%, 86.2% and 93.6% (p=0.58), whereas among patients with no
drug changes, the adherence rates were 95%, 96% and 97.4% in the early, late and
sequential treatment arms, respectively (p=0.48).
Risk factors associated with drug switches and complete regimen change in co-treated
patients
Treatment arm was not associated with drug switches and complete regimen changes.
Baseline CD4+ cell count < 50 cells/mm3 was significantly associated with complete
regimen change (HR: 4.7; 95% CI: 1.6 to 14.0; p=0.005) compared to CD4+ cell count ≥50
cells/mm3. Additionally, patients with a BMI greater than 25 kg/m2 were more likely to
experience complete regimen change (HR: 3.3; 95% CI: 1.4–7.8; p=0.01) compared to
patients with BMI 18.5–25 kg/m2. (Table 4)
Discussion
We demonstrated similar incidence of ART drug switches irrespective of the timing of ART
initiation relative to the start of TB treatment, providing evidence that potentiated drug
toxicity may be of limited concern in TB-HIV co-treatment. Low rates of drug switching
due to toxicity was observed in all three arms, with no significant difference in the incidence
of drug switching between the treatment arms, although the number of drug switches was
higher in the early and late integrated compared to the sequential treatment arm. The
regimen chosen for this study provided a once-daily option at a time before the availability
of tenofovir, to be taken with once daily TB treatment. Reports from two other randomised
controlled trials also show similar rates of toxicity in patients who start ART early (within 2
weeks), or later (within 8 weeks), in the course of TB treatment. In the STRIDE study, 44%
and 47% of patients experienced grade 3 and 4 adverse events, with 14/405 patients in the
early group; and 7 /401 patients in the late-ART group switching ART regimen for toxicity,
respectively [7]. Likewise, the CAMELIA study found similar incidence of drug-related
adverse events; 2.93 (95% CI, 2.58 to 3.32) and 3.21 (95% CI, 2.83 to 3.63) events per 100
person months in the earlier and later ART groups respectively [8]. The first line ARV
treatment regimen used in the STRIDE and CAMELIA studies, included once daily
efavirenz, emtricitabine and tenofovir and efavirenz, lamivudine and stavudine taken twice
daily, respectively.
Data on rates of adverse events and drug switches due to toxicity in patients receiving
therapy for both HIV and tuberculosis are limited. Observational studies in TB-HIV co-
treatment demonstrate conflicting rates of drug related adverse events, compared to evidence
to the contrary from the three relatively large randomized controlled trials. A retrospective
study from South Africa showed that the occurrence of serious adverse events was unrelated
to the use of antiretroviral drugs in patients with TB [10]. However, retrospective studies
conducted in Thailand and India, among patients with CD4 < 100 cells/mm3, found drug-
related adverse events occurred in 66.1% of co-treated patients in the first 2 months of TB
treatment [11], and that concomitant use of ART and TB treatment was a predictor of
adverse events (OR: 1.88) [12]. Notably, in these two relatively small studies (< 150
patients), two third of all patients received a NVP-containing ART regimen, whereas almost
all of our patients were initiated on an EFV-based ART regimen.
Previous studies have shown that peripheral neuropathy (43%) and hepatoxocity (5–10%)
are the most common toxicities in patients receiving TB-HIV co-treatment [7, 13–15]. The
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most common cause of drug switching in our study was neuropsychiatric toxicity, most
likely related to the use of an EFV-based first line regimen. Contrary to other studies,
describing the increased risk of hepatotoxicity when ART is introduced during the intensive
phase of TB therapy [15], there were no drug switch for treatment limiting hepatotoxicity
among patients in the early integrated treatment arm. However, drug switch for
hepatotoxicity was observed in the late integrated and sequential treatment arms. This may
be as a result of patients having lower CD4+ cell counts due to delay in initiation of
ART[15]. While studies that report an increased risk of hepatotoxicity in TB-HIV co-
treatment cite baseline elevated transaminases and hepatitis B antigenaemia as likely risk
factors [16–25], the prevalence of both conditions was low in our study, which may account
for the small number of drug switch from hepatotoxicty that were observed.
It is likely that the profile of toxicities presenting in this cohort is linked to our choice of
first line ART regimen, which was chosen for its suitability to be co-administered with
directly observed TB treatment and once daily dosing. The absence of clinically significant
alteration of efavirenz plasma concentration when co-administered with rifampicin has been
demonstrated [26, 27]. Efavirenz has also been shown to have a lower risk of hepatotoxicity
than nevirapine [25]. Enteric coated didanosine (ddI-EC) has a lower risk of peripheral
neuropathy and gastro-intestinal toxicities than stavudine and buffered ddI [14], the
available NRTIs at the time of study conduct.
In addition, this study was conducted in ambulant, relatively clinically stable patients with
TB disease mainly confined to the lungs. Although other nucleoside/nucleotide reverse
transcriptase options, included in fixed-dose combinations, have now eclipsed didanosine-
containing regimens as the first-line options, enteric-coated didanosine may still provide a
useful alternative in patients unable to tolerate the alternative once-daily options[28].
Despite the additional pill burden when TB and ART therapy was co-administered in the
early and late integrated treatment arms, the adherence was similar across the three
treatment arms. The incidence of ART complete regimen change from virological failure
was low and did not differ by treatment arm, despite the addition of 3 ARVs to the 4-drug
intensive phase of TB or to the 2 drug maintenance phase of TB therapy. Similar high rates
of virological suppression were achieved and sustained, through to 18 months of follow-up
after ART initiation across all study arms. These rates were similar to rates achieved at 48
and 50 weeks in the STRIDE and CAMELIA studies respectively [7, 8], and better than
reports of virological suppression rates (76%) achieved in treatment programmes from sub-
Saharan Africa at 12 months [29].
The higher incidence of complete regimen change in patients with CD4 <50cells/mm3
observed in this study has also been reported in other TB and non-TB settings [30–33].
Several studies have shown that low CD4+ cell counts are a predictor for complete regimen
change due to virological failure. [34–36]. The drug switches in patients will low CD4+ cell
counts may not be directly associated with TB HIV co-treatment, but may instead be due to
the presence of other co-morbidities in patients with advanced HIV disease.
Low BMI has been shown in previous studies to be associated with poor treatment outcomes
and a potential predictor of treatment failure in resource constrained settings [34–36]. In
contrast our study found higher BMI >25 kg/m2, to be associated with a higher risk of
complete regimen change, this may in part, be explained by findings from other studies
which found sub-therapeutic drug levels [37] and BMI > 25 kg/m2 to be an independent risk
factor for virological failure [38]
The following study limitations need to be considered. We included ambulant patients with
CD4+cell count up to 500 cells mm3, higher than the CD4 threshold for ART in current
Naidoo et al. Page 6













WHO and South African ART treatment guidelines. The inclusion of patients less advanced
in the course of their HIV disease may have led to an under-estimation of the true effect of
additive toxicity when co-treating TB-HIV. In this study, ART drug switches were triggered
by grade 3 or 4 toxicities. However, grade 1 and 2 toxicities may affect adherence to therapy
or patients’ quality of life. Interruptions to TB drug therapy are also not included in this
analysis. Pillcount as a measure of adherence reported in this study, may have over-
estimated the adherence reported.
Conclusion
Both drug switches and complete regimen changes were uncommon in patients co-treated
for TB-HIV, using a didanosine, lamivudine and efavirenz first-line regimen. Manageable
treatment-limiting toxicities occurred early, and affected a small percentage of the trial
participants. The survival benefit from early initiation of ART in TB-HIV co-infected
patients outweighed the concerns of treatment-limiting toxicities. Low CD4 count and
higher BMI (>25), at baseline increased the risk of treatment failure and complete regimen
change, although the association with higher BMI may need further validation.
Patients with severe immunosuppression need to be monitored carefully, using viral load
determinations, as they were most at risk for treatment failure requiring regimen change.
The additional pill burden with combined TB-HIV treatment did not have a significant effect
on adherence to ART in this study. These data further strengthen the available evidence of
the benefits of integrating TB-HIV treatment and underline the continued usefulness of
alternative once-daily regimens in such settings.
Acknowledgments
We thank the patients for their participation in this study; Mrs Anneke Grobeler for statistical support; Ms Natasha
Samsunder for laboratory support, Dr Aarthie Singh and Dr Munira Khan for additional clinical support. Faldie
Burton for data management; Mrs Cheryl Baxter for editorial assistance; and all other member of the SAPiT study
team. CAPRISA was established as part of the Comprehensive International Program of Research on AIDS
(CIPRA) (grant # AI51794) from the US National Institutes of Health. The US President’s Emergency Plan for
AIDS Relief (PEPfAR) funded the care of all the participants in the trial. The Global Fund to fight AIDS,
Tuberculosis and Malaria funded the cost of the drugs used in the trial. The research infrastructure to conduct this
trial, including the data management, laboratory and pharmacy cores were established through the CIPRA grant. Dr
K Naidoo, Dr N Padayatchi and Ms Tanuja Gengiah were supported by the Columbia University-Southern African
Fogarty AIDS International Training and Research Program (AITRP) funded by the Fogarty International Center,
National Institutes of Health (grant # D43TW00231).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of
the report. All authors had access to data, commented on drafts, and approved the final report. The corresponding
author had final responsibility for the decision to submit for publication.
References
1. W.H.O. Global Tuberculosis Control Report. Geneva, Switzerland: 2012. www.who.int/tb/data
2. Lalloo UG. Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas? Clin
Infect Dis. 2009; 48:1760–1762. [PubMed: 19438396]
3. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in
patients with and without HIV co-infection. Thorax. 2004; 59:704–707. [PubMed: 15282393]
4. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution
events in HIV-related tuberculosis. Int J Tuberc Lung Dis. 2007; 11:1282–1289. [PubMed:
18229435]
5. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during
tuberculosis therapy. N Engl J Med. 2010; 362:697–706. [PubMed: 20181971]
Naidoo et al. Page 7













6. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis
treatment. N Engl J Med. 2011; 365:1492–1501. [PubMed: 22010915]
7. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-
infected adults with tuberculosis. N Engl J Med. 2011; 365:1471–1481. [PubMed: 22010913]
8. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and
tuberculosis. N Engl J Med. 2011; 365:1482–1491. [PubMed: 22010914]
9. National Institiute of Allergy and Infectious Diseases. Division of AIDS Table for grading the
severity of adult and pediatric adverse events. Bethesda, MD: 2004. (URL: http://
www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/
daidsaegradingtable.pdf.)
10. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to anti-tuberculosis therapy:
influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009; 20:339–345. [PubMed:
19386972]
11. Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral
therapy with tuberculosis. Southeast Asian J Trop Med Public Health. 2007; 38:1053–1060.
[PubMed: 18613546]
12. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era
of highly active antiretroviral therapy. AIDS. 2002; 16:75–83. [PubMed: 11741165]
13. Gengiah TN, Gray AL, Naidoo K, Abdool Karim Q. Initiating antiretrovirals during tuberculosis
treatment: a drug safety review. Expert Opinion on Drug Safety. 2011; 10:559–574. [PubMed:
21204737]
14. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution
in first-line antiretroviral therapy. Clin Infect Dis. 2009; 48:1617–1623. [PubMed: 19385733]
15. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy
cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007; 21:1301–1308. [PubMed:
17545706]
16. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with
antiretroviral therapy in adults infected with human immunodeficiency virus and the role of
hepatitis C or B virus infection. JAMA. 2000; 283:74–80. [PubMed: 10632283]
17. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with
nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Hepatology. 2002; 35:182–189. [PubMed: 11786975]
18. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Filice G. Hepatotoxicity and nelfinavir: a meta-
analysis. Clin Gastroenterol Hepatol. 2005; 3:482–488. [PubMed: 15880318]
19. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and
the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;
14:2895–2902. [PubMed: 11153671]
20. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe
hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002; 186:23–31.
[PubMed: 12089658]
21. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral
therapy in the HIV-NAT Cohort, Thailand, 1996–2001. AIDS. 2003; 17:2191–2199. [PubMed:
14523276]
22. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of
highly active antiretroviral therapy. The ATHENA cohort. AIDS. 2002; 16:737–745. [PubMed:
11964530]
23. Lodenyo H, Schoub B, Ally R, Kairu S, Segal I. Hepatitis B and C virus infections and liver
function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J.
2000; 77:13–15. [PubMed: 10944831]
24. Matee MI, Magesa PM, Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis
B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in
Dar es Salaam, Tanzania. BMC Public Health. 2006; 6:21. [PubMed: 16445860]
Naidoo et al. Page 8













25. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy
with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a
randomised open-label trial, the 2NN Study. Lancet. 2004; 363:1253–1263. [PubMed: 15094269]
26. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz
800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
AIDS. 2006; 20:131–132. [PubMed: 16327334]
27. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz
clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol. 2012; 68:689–
695. [PubMed: 22108776]
28. Antiretroviral therapy for HIV infection in adults and adolecents: recommendations for a public
health approach-2010 revision. Geneva: World Health Organization; 2010.
29. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up
of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic
review. Lancet Infect Dis. 2010; 10:155–166. [PubMed: 20185094]
30. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral
load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS. 2005;
19:463–471. [PubMed: 15764851]
31. Robbins GK, Johnson KL, Chang Y, et al. Predicting virologic failure in an HIV clinic. Clin Infect
Dis. 2010; 50:779–786. [PubMed: 20121574]
32. Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of
antiretroviral treatment failure in treatment-naive HIV-infected patients at Chiang Mai University
Hospital, Thailand. AIDS Research and Therapy. 2011; 8:42. [PubMed: 22060823]
33. Fox MP, Cutsem GV, Giddy J, et al. Rates and predictors of failure of first-line antiretroviral
therapy and switch to second-line ART in South Africa. JAIDS. 2012; 60:428–437. [PubMed:
22433846]
34. Colebunders R, Moses KR, Laurence J, et al. A new model to monitor the virological efficacy of
antiretroviral treatment in resource-poor countries. Lancet Infect Dis. 2006; 6:53–59. [PubMed:
16377535]
35. Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic
antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.
BMC Infect Dis. 2009; 9:81. [PubMed: 19493344]
36. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of
antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;
367:817–824. [PubMed: 16530575]
37. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug
monitoring in treatment-naive and -experienced HIV-1-infected patients. JAIDS. 2007; 46:433–
442. [PubMed: 17786128]
38. van Griensven J, Zachariah R. Increased baseline body weight is a risk factor associated with
virological failure while on antiretroviral treatment. JAIDS. 2008; 48:631–633. [PubMed:
18665026]
Naidoo et al. Page 9














SAPiT trial: Screening, randomization, and follow-up of study participants, demonstrating
distribution of patients with drug switches due to toxicity and complete regimen change due
to virological failure
*1 patient experienced 2 individual drug switches due to toxicity for different reasons in the
early integrated arm (9 drug switches and 16 ARV drug changes in total) but only the initial
drug switch is illustrated in this figure and used in the incidence rate calculation.
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